FDA Investigator Pete Amin (Pankaj)
Pete Amin (Pankaj) has conducted inspections on 2 sites in 1 countries as of 18 Oct 2021. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
2
Last Inspection Date:
18 Oct 2021
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Pete Amin (Pankaj):
Andrew F Shrake,
Ashley L Reiber,
Bo Chi, PhD,
Brenda W Uratani, PhD,
Brentley S Collins,
Brian D Nicholson,
Burnell M Henry,
Candace Y Gomez Broughton,
Carrie Ann Plucinski,
Claire M Minden,
David Perkins,
Deborah M Trout,
Debra I Love,
Donald C Obenhuber, PhD,
Dr. Robert C Horan, MD,
Eliezar Ramos,
Ellen P Madigan,
Gene D Arcy,
Gregory Price,
Humera T Khan,
Jacek Cieslak, PhD,
Jacqueline Mdiaz Albertini,
Jason F Chancey,
Jeanne M Morris,
Jennifer L Schmidt,
John Godshalk,
John M Seale,
John S Hartford,
Kalavati Suvarna, PhD,
L Norwood,
Laura Fontan, MS,
Laurie Graham,
LCDR Debra Emerson,
LCDR Randall L Morris,
Lewis K Antwi,
Lori A Holmquist,
M Pedgen,
Mariza M Jafary,
Marlene G Swider,
Mary Jeanet Mcgarry,
Megan A Haggerty,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Obinna R Echeozo,
Omotunde O Osunsanmi,
Pankaj H Amin,
Patricia F Hughes, PhD,
Prabhu P Raju,
Priscilla M Pastrana,
Ramon E Martinez,
Ranjani Prabhakara,
Rashmi Rawat, PhD,
Richard Heath Coats,
Richard T Riggie,
Robert J Martin,
Rose Ashley,
Russell K Riley,
Samuel W Labinjo,
Scott R Nichols, PhD,
Sean R Marcsisin,
Stacey S Degarmo,
Stephen D Brown,
Susan M Jackson,
Susan P Bruederle,
Svetlana A Shestopal,
Unnee Ranjan,
Vijaya L Simhadri,
Wayne E Seifert,
Yonggang Wang, PhD
Pete Amin (Pankaj)'s Documents
Publish Date | Document Type | Title |
---|---|---|
April, 2003 | EIR | CSL Behring L.L.C. - EIR, 2003-04-01 |
April, 2003 | FDA 483 | CSL Behring L.L.C. - Form 483, 2003-04-01 |
October, 2021 | FDA 483 | Lonza Biologics, Inc. - Form 483, 2021-10-22 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more